Gout Exercises

Gout Exercises 8 out of 10 based on 111 ratings.
 

Savient Announces Named Patient Programme for KRYSTEXXA in the European Union for Patients with Refractory Chronic Gout We believe that KRYSTEXXA can address a significant unmet medical need globally and we remain committed to provide this therapy to those patients who suffer from this crippling debilitating disease and have no other treatment options available to them” said Kenneth Gout Exercises Bahrt M. D. Senior Vice President and Chief Medical Officer of Savient Pharmaceuticals Inc. Gout Gout Exercises Exercises idis develops and implements Managed Access Programmes that allow patients with unmet medical needs to access medicines that are not available through the traditional clinical trial or commercial framework. For this programme Idis will facilitate access to KRYSTEXXA on a named patient basis to European hospitals pharmacies physicians on behalf of their patients. Under a Named Patient Programme treatments that are pending approval by the European Medicines Agency EMA can be legally administered to patients who are suffering from serious diseases until they are commercially available in each market. Savient is seeking approval for KRYSTEXXA in Europe and filed its regulatory application with the EMA in May 2011.

Savient Announces Named Patient Programme for KRYSTEXXA in the European Union for Patients with Refractory Chronic Gout We believe that KRYSTEXXA can address a significant unmet medical need globally and we remain committed to provide this therapy to those patients who suffer from this crippling debilitating disease and have no other treatment options available to them” said Kenneth Bahrt M. D. Senior Vice President and Chief Medical Officer of Savient Pharmaceuticals Inc. Idis develops and implements Managed Access Programmes that allow patients with unmet medical needs to access medicines that are not available through the traditional clinical trial or commercial framework. For this programme Idis will facilitate access to KRYSTEXXA on a named patient basis to European hospitals pharmacies physicians on behalf of their patients. Under a Named Patient Programme treatments that are pending approval by the European Medicines Agency EMA can be legally administered to patients who are suffering from serious diseases until they are commercially available in each market. Savient is seeking approval for KRYSTEXXA in Europe and filed its regulatory application with the EMA in May 2011.

Idis is the leading expert in developing implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients. Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987 Idis has developed and managed access to thousands of medicines from virtually every therapeutic category impacting the lives of hundreds of thousands of patients in countries around the world.

Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University “Duke” and Mountain View Pharmaceuticals Inc. “MVP”. Duke developed the recombinant uricase enzyme and MVP developed the PEG ylation technology used in the manufacture of KRYSTEXXA.

Since 1987 Idis has developed and managed access to thousands of medicines from virtually every therapeutic category impacting the lives of hundreds of thousands of patients in countries around the world. These risks trends and uncertainties are in some instances beyond our control. Words such as “anticipate” “believe” “estimate” “expect” “intend” “plan” “will” and other similar expressions identify forward-looking statements although not all forward-looking statements contain these identifying words. In particular any statements regarding the safety and efficacy of KRYSTEXXA status of our KRYSTEXXA marketing efforts and additional plans related thereto market demand and reimbursement for KRYSTEXXA our view of the refractory chronic gout RCG market size and our market expansion plans including our MAA filing before the EMA are forward-looking statements.

Although most cases

Gout Exercises

of gout can be controlled with conventional urate-lowering therapy when uric acid levels remain high and symptoms persist despite treatment efforts chronic gout may be defined as refractory. Savient Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXApegloticase for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University “Duke” and Mountain View Pharmaceuticals Inc.

Words such as “anticipate” “believe” “estimate” “expect” “intend” “plan” “will” and other similar expressions identify forward-looking statements although not all forward-looking statements contain these identifying words. In particular any statements regarding the safety and efficacy of KRYSTEXXA status of our KRYSTEXXA marketing efforts and additional plans related thereto market demand and reimbursement for KRYSTEXXA our view of the refractory chronic gout RCG market size and our market expansion plans including our MAA filing before the EMA are forward-looking statements. These forward-looking Gout Exercises statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information current expectations assumptions estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. We may not actually achieve the plans intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements which speak only as of the date of publication of this press release. Actual results or events could differ materially from the plans intentions and expectations disclosed in the forward-looking statements that we make.

Idis is the leading expert Gout Exercises in developing implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients. Idis has 25 years experience of partnering with pharmaceutical and

Gout Exercises

biotechnology companies to create regulatory-compliant ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987 Idis has developed and managed access to thousands of medicines from virtually every therapeutic category impacting the lives of hundreds of thousands of patients in countries around the world.

. :

  • Idis is the leading expert in developing implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients
  • A significant sub-population of gout patients approximately 120000 are burdened with a difficult-to-treat form of the condition known as refractory chronic gout RCG
  • MVP”
  • Patients receiving re-treatment may be at increased risk for anaphylaxis and infusion reactions and should be monitored carefully

http://alumnus.caltech.edu/~natalia/studyinus/guide/sad.htm
http://gouthomecure.com/gout-photos-toes/
http://rad.usuhs.edu/medpix/tf_case.html?pt_id=8273&quiz=no
http://gouthomecure.com/food-for-preventing-gout/
http://gouthomecure.com/gout-treatment-dietary/
http://www.georgiahealth.edu/medicine/medicine/Rheumatology/faculty/Oliver.html
http://gouthomecure.com/gout-treatment-in-big-toe/

Tags: , <BR/>

Leave a Reply

You must be logged in to post a comment.